Scott D Sandell's Net Worth

$3.58 Billion

Who is Scott D Sandell?

Scott D Sandell has an estimated net worth of $3.58 Billion. This is based on reported shares across multiple companies, which include Sagimet Biosciences Inc., Cloudflare, Inc., Desktop Metal, Inc., RHYTHM PHARMACEUTICALS, INC., OPOWER, INC., Cascadian Therapeutics, Inc., Workday, Inc., Care.com Inc, Millennial Media Inc., AEROHIVE NETWORKS, INC, PHARMOS CORP, Echo Global Logistics, Inc., Arcellx, Inc., FUSION-IO, INC., Data Domain, Inc., PHARMION CORP, MULESOFT, INC, GLU MOBILE INC, TriVascular Technologies, Inc., INNERWORKINGS INC, INTERCELL USA, INC., Robinhood Markets, Inc., HYPERION THERAPEUTICS INC, Elastic N.V., Nkarta, Inc., Senseonics Holdings, Inc., Berkshire Grey, Inc., Bright Health Group Inc., Verona Pharma plc, SUPERNUS PHARMACEUTICALS INC, CHANNELADVISOR CORP, BuzzFeed, Inc., Monte Rosa Therapeutics, Inc., Bloom Energy Corp, Oyster Point Pharma, Inc., Groupon, Inc., AVEO PHARMACEUTICALS, INC., Zosano Pharma Corp, Sprout Social, Inc., APPIAN CORP, Mersana Therapeutics, Inc., Clovis Oncology, Inc., Mirum Pharmaceuticals, Inc., Adaptimmune Therapeutics PLC, AMICUS THERAPEUTICS INC, VONAGE HOLDINGS CORP, IonQ, Inc., BOX INC, Coursera, Inc., Nightstar Therapeutics plc, Tintri, Inc., Loxo Oncology, Inc., Dermira, Inc., CHAMPIONS ONCOLOGY, INC., Surface Oncology, Inc., Reneo Pharmaceuticals, Inc., TREVENA INC, GENOCEA BIOSCIENCES, INC., Metacrine, Inc., PhaseBio Pharmaceuticals Inc, Inozyme Pharma, Inc., Millendo Therapeutics, Inc., CVRx, Inc., TARGACEPT INC, TESARO, Inc., Eargo, Inc., PROTEOSTASIS THERAPEUTICS, INC., ARDELYX, INC., Galera Therapeutics, Inc., Savara Inc, Trevi Therapeutics, Inc., GLYCOMIMETICS INC, Tracon Pharmaceuticals, Inc., Annexon, Inc., SYNLOGIC, INC., Epizyme, Inc., SUNESIS PHARMACEUTICALS INC, MINERVA SURGICAL INC, Akouos, Inc., Black Diamond Therapeutics, Inc., Arsanis, Inc., Transcept Pharmaceuticals Inc, Cerecor Inc., Roka BioScience, Inc., Regulus Therapeutics Inc., ARCA biopharma, Inc., IMARA Inc., Marker Therapeutics, Inc., Casper Sleep Inc., Omthera Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc., ZeroFox Holdings, Inc., Tableau Software Inc, MOTRICITY INC, Senti Biosciences, Inc.\, Strongbridge Biopharma plc, Neutral Tandem Inc, CVENT INC, Achaogen Inc, Vitae Pharmaceuticals, Inc, XOOM Corp, SOURCEFIRE INC, Liquidia Technologies Inc, BOINGO WIRELESS INC, AUDIENCE INC, ARADIGM CORP, INTERLEUKIN GENETICS INC, INHIBITEX, INC., MYOGEN INC, PEPLIN INC, HEMOSENSE INC, ARYx Therapeutics, Inc., Korro Bio, Inc., INTARCIA THERAPEUTICS, INC, and ZTI MERGER SUBSIDIARY III INC.

SEC CIK

Scott D Sandell's CIK is 0001237289

Past Insider Trading and Trends

2021 was Scott D Sandell's most active year for acquiring shares with 102 total transactions. Scott D Sandell's most active month to acquire stocks was the month of May. 2021 was Scott D Sandell's most active year for disposing of shares, totalling 112 transactions. Scott D Sandell's most active month to dispose stocks was the month of October. 2022 saw Scott D Sandell paying a total of $378,973,733.85 for 18,666,606 shares, this is the most they've acquired in one year. In 2019 Scott D Sandell cashed out on 145,573,724 shares for a total of $954,668,588.20, their largest year based on trade value.